$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000117867022000013 Filed on February 10, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$844.3M	$163.6M	$492.9M
YoY Change	71.31%	128.18%	124.28%
Cost Of Revenue	$115.0M	$23.00M	$74.19M
YoY Change	55.02%	88.52%	196.01%
Gross Profit	$729.3M	$140.5M	$418.7M
YoY Change	74.19%	136.13%	115.05%
Gross Profit Margin	86.38%	85.9%	84.95%
Selling, General & Admin	$620.6M	$166.3M	$588.4M
YoY Change	5.48%	6.4%	22.84%
% of Gross Profit	85.1%	118.36%	140.55%
Research & Development	$792.2M	$168.5M	$654.8M
YoY Change	20.97%	-16.29%	-0.05%
% of Gross Profit	108.62%	119.93%	156.41%
Depreciation & Amortization	$36.80M	$10.40M	$30.20M
YoY Change	21.85%	89.09%	81.93%
% of Gross Profit	5.05%	7.4%	7.21%
Operating Expenses	$1.413B	$334.8M	$1.243B
YoY Change	13.64%	-6.38%	9.62%
Operating Profit	-$708.7M	-$194.3M	-$828.4M
YoY Change	-14.46%	-34.82%	-11.81%
Interest Expense	$143.0M	-$27.40M	$84.50M
YoY Change	69.26%	-475.34%
% of Operating Profit
Other Income/Expense, Net	-$143.5M	-$22.00M	-$27.16M
YoY Change	428.28%	-254.93%	-150.13%
Pretax Income	-$852.1M	-$243.6M	-$855.6M
YoY Change	-0.4%	-11.93%	-3.35%
Income Tax	$700.0K	-$100.0K	$2.681M
% Of Pretax Income
Net Earnings	-$852.8M	-$243.5M	-$858.3M
YoY Change	-0.64%	-11.82%	-3.14%
Net Earnings / Revenue	-101.01%	-148.9%	-174.15%
Basic Earnings Per Share	-$7.20		-$7.46
Diluted Earnings Per Share	-$7.20	-$2.094M	-$7.46
COMMON SHARES
Basic Shares Outstanding	118.5M shares	116.2M shares	115.0M shares
Diluted Shares Outstanding	118.5M shares		115.0M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.436B	$1.830B	$1.874B
YoY Change	29.94%	20.21%	22.02%
Cash & Equivalents	$820.0M	$496.6M	$496.6M
Short-Term Investments	$1.616B	$1.333B	$1.378B
Other Short-Term Assets	$88.08M	$62.80M	$62.80M
YoY Change	40.25%	-21.79%	-21.79%
Inventory	$86.36M	$75.20M	$75.20M
Prepaid Expenses
Receivables	$125.3M	$102.4M	$68.90M
Other Receivables	$73.27M	$533.5M	$533.5M
Total Short-Term Assets	$2.809B	$2.615B	$2.615B
YoY Change	7.41%	52.39%	52.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$733.6M	$465.0M	$706.5M
YoY Change	3.84%	9.37%	9.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$101.1M	$45.05M	$85.80M
YoY Change	17.83%	149.29%	160.79%
Total Long-Term Assets	$834.7M	$792.3M	$792.3M
YoY Change	5.36%	16.64%	16.65%
TOTAL ASSETS
Total Short-Term Assets	$2.809B	$2.615B	$2.615B
Total Long-Term Assets	$834.7M	$792.3M	$792.3M
Total Assets	$3.643B	$3.407B	$3.407B
YoY Change	6.93%	42.25%	42.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$73.43M	$51.97M	$52.00M
YoY Change	41.2%	4.17%	4.21%
Accrued Expenses	$435.7M	$355.9M	$392.8M
YoY Change	10.93%	80.48%	74.66%
Deferred Revenue		$127.2M
YoY Change		63.46%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$695.7M	$585.3M	$585.3M
YoY Change	18.86%	65.99%	66.0%
LONG-TERM LIABILITIES
Long-Term Debt	$675.7M	$191.3M	$191.3M
YoY Change	253.21%
Other Long-Term Liabilities	$1.684B	$37.91M	$1.614B
YoY Change	4.3%	306.3%	167.36%
Total Long-Term Liabilities	$2.359B	$37.91M	$1.806B
YoY Change	30.67%	306.3%	199.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$695.7M	$585.3M	$585.3M
Total Long-Term Liabilities	$2.359B	$37.91M	$1.806B
Total Liabilities	$3.055B	$2.391B	$2.391B
YoY Change	27.79%	149.97%	149.98%
SHAREHOLDERS EQUITY
Retained Earnings		-$4.585B
YoY Change		23.03%
Common Stock		$5.645B
YoY Change		8.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$588.2M	$1.016B	$1.016B
YoY Change
Total Liabilities & Shareholders Equity	$3.643B	$3.407B	$3.407B
YoY Change	6.93%	42.25%	42.25%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$852.8M	-$243.5M	-$858.3M
YoY Change	-0.64%	-11.82%	-3.14%
Depreciation, Depletion And Amortization	$36.80M	$10.40M	$30.20M
YoY Change	21.85%	89.09%	81.93%
Cash From Operating Activities	-$641.7M	-$123.2M	-$615.0M
YoY Change	4.35%	-37.14%	120.87%
INVESTING ACTIVITIES
Capital Expenditures	$76.37M	-$21.70M	$70.36M
YoY Change	8.54%	-44.07%	-49.8%
Acquisitions
YoY Change
Other Investing Activities	$4.198M	-$76.30M	$5.300M
YoY Change	-20.79%	-58.08%	-24.29%
Cash From Investing Activities	-$273.3M	-$97.90M	-$435.5M
YoY Change	-37.25%	-55.68%	4.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.247B	218.0M	$995.0M
YoY Change	25.34%	439.6%	20.87%
NET CHANGE
Cash From Operating Activities	-$641.7M	-123.2M	-$615.0M
Cash From Investing Activities	-$273.3M	-97.90M	-$435.5M
Cash From Financing Activities	$1.247B	218.0M	$995.0M
Net Change In Cash	$323.1M	-3.100M	-$50.58M
YoY Change	-738.78%	-99.18%	-139.83%
FREE CASH FLOW
Cash From Operating Activities	-$641.7M	-$123.2M	-$615.0M
Capital Expenditures	$76.37M	-$21.70M	$70.36M
Free Cash Flow	-$718.1M	-$101.5M	-$685.3M
YoY Change	4.78%	-35.43%	63.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021	dei	Entity File Number EntityFileNumber	001-36407
CY2021	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	551-8200
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2021	dei	Trading Symbol TradingSymbol	ALNY
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	19996896335	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	120210498	shares
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	819975000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	496580000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1548617000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1333182000	USD
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	66972000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	44633000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	198571000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	102413000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	86363000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	75202000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	88078000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	62767000	USD
CY2021Q4	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	0	USD
CY2020Q4	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	500000000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2808576000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2614777000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	501958000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	465029000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	231675000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	241485000	USD
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40891000	USD
CY2020Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40725000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60204000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45045000	USD
CY2021Q4	us-gaap	Assets Assets	3643304000	USD
CY2020Q4	us-gaap	Assets Assets	3407061000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	73426000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	51966000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	395174000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	355909000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40548000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	36872000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	149483000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	127207000	USD
CY2021Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	37079000	USD
CY2020Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	13316000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	695710000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	585270000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	281347000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	293039000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	152360000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	225094000	USD
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	675697000	USD
CY2020Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	191278000	USD
CY2021Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1151024000	USD
CY2020Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1058225000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	98963000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37908000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	3055101000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2390814000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116427000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	116427000	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1164000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120182000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120182000	shares
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6058453000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5644074000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33259000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-939431000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1202000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43622000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5438193000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4585369000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	588203000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3643304000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3407061000	USD
CY2021	us-gaap	Revenues Revenues	844287000	USD
CY2020	us-gaap	Revenues Revenues	492853000	USD
CY2019	us-gaap	Revenues Revenues	219750000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	115005000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	74185000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	25062000	USD
CY2021	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	25139000	USD
CY2020	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	3867000	USD
CY2019	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	0	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	792156000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	654819000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	655114000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	620639000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	588420000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	479005000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	1552939000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1321291000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1159181000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-708652000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-828438000	USD
CY2021	us-gaap	Interest Expense InterestExpense	143021000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	33448000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2050000	USD
CY2020	us-gaap	Interest Expense InterestExpense	84496000	USD
CY2019	us-gaap	Interest Expense InterestExpense	0	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1579000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	11809000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	45525000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20730000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-143492000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27162000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	54178000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-852144000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-855600000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-885253000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	680000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.20
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2681000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	863000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-852824000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-858281000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-886116000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.20
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.46
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.46
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.11
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.11
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118451000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118451000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114986000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114986000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109264000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109264000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-852824000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-858281000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-886116000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1978000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	211000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	558000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	11398000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-7081000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-343000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-943000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	234000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	3520000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10363000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7104000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3305000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	772477000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-842461000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-865385000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-889421000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1301965000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	63499000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	7909000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	5033000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	177230000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3305000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-886116000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1438692000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	189371000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	11083000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99498000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	142988000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7104000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-858281000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	232486000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	13631000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	168300000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10363000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-852824000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	588203000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-852824000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-858281000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-886116000	USD
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	47567000	USD
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	34772000	USD
CY2019	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	17175000	USD
CY2021	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	42127000	USD
CY2020	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	39663000	USD
CY2019	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	37193000	USD
CY2021	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	116562000	USD
CY2020	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	84496000	USD
CY2019	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	165717000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	139873000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	174841000	USD
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	55695000	USD
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	54042000	USD
CY2019	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	11288000	USD
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	57676000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	11259000	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-12613000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	101799000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	56236000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24238000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26415000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	35426000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	32411000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	32093000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13017000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9530000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	88240000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	143732000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	92354000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-50404000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-43965000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	392251000	USD
CY2021	alny	Operating Lease Payments Including Prepayment Adjustment OperatingLeasePaymentsIncludingPrepaymentAdjustment	40352000	USD
CY2020	alny	Operating Lease Payments Including Prepayment Adjustment OperatingLeasePaymentsIncludingPrepaymentAdjustment	33823000	USD
CY2019	alny	Operating Lease Payments Including Prepayment Adjustment OperatingLeasePaymentsIncludingPrepaymentAdjustment	16045000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-641693000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-614961000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-278427000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76372000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70361000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	140156000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1656114000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2025626000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2075925000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1463550000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1691669000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1775404000	USD
CY2021	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	41975000	USD
CY2020	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
CY2019	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	30000000	USD
CY2021	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	42141000	USD
CY2020	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	25900000	USD
CY2019	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	USD
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4198000	USD
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5300000	USD
CY2019	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	7000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-273300000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-435518000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-417677000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	246268000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	200484000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	71284000	USD
CY2021	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	500000000	USD
CY2020	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	500000000	USD
CY2019	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	0	USD
CY2021	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	19600000	USD
CY2020	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	8400000	USD
CY2019	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381900000	USD
CY2021	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	500000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	200000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	99498000	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	400000000	USD
CY2021	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	18750000	USD
CY2020	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	13403000	USD
CY2019	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	30000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1247118000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	994979000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	823184000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9018000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4918000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-83000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	323107000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50582000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	126997000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499046000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	549628000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	422631000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	822153000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499046000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	549628000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	24657000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	172000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13599000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14518000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14876000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7932000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	34435000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4530000	USD
CY2021	alny	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	0	USD
CY2020	alny	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	500000000	USD
CY2019	alny	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top five biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, we have four products that have received marketing approval, including one partnered product, and five late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from three commercialized products, ONPATTRO, GIVLAARI and OXLUMO, primarily in the United States, or U.S., Europe and Japan.</span></div>
CY2021Q4	alny	Number Of Products With Marketing Approval NumberOfProductsWithMarketingApproval	4	product
CY2021Q4	alny	Number Of Partnered Products NumberOfPartneredProducts	1	product
CY2021Q4	alny	Number Of Clinical Programs In Late Stages NumberOfClinicalProgramsInLateStages	5	program
CY2021Q4	alny	Number Of Commercialized Products NumberOfCommercializedProducts	3	product
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk and Significant Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially expose us to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of December 31, 2021 and 2020, substantially all of our cash, cash equivalents and marketable securities were invested in money market funds, certificates of deposit, commercial paper, corporate notes, U.S. government-sponsored enterprise securities and U.S. treasury securities through highly rated financial institutions. Corporate notes may also </span></div>include foreign bonds denominated in U.S. dollars. Investments are restricted, in accordance with our investment policy, to a concentration limit per issuer.
CY2021	alny	Investments Classified As Cash And Cash Equivalent Original Maturities InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities	P90D
CY2021	alny	Investment Maturity Period Minimum InvestmentMaturityPeriodMinimum	P90D
CY2020Q4	alny	Capitalized Inventory CapitalizedInventory	0	USD
CY2021	us-gaap	Depreciation Depreciation	36800000	USD
CY2020	us-gaap	Depreciation Depreciation	30200000	USD
CY2019	us-gaap	Depreciation Depreciation	16600000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	97433000	USD
CY2021Q4	alny	Accrued Pre Clinical Clinical Trial And Manufacturing Current AccruedPreClinicalClinicalTrialAndManufacturingCurrent	83534000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11225000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12852000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13818000	shares
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	95107000	USD
CY2021	alny	Valuation Allowances And Reserves Provision Related To Current Period Sales ValuationAllowancesAndReservesProvisionRelatedToCurrentPeriodSales	187978000	USD
CY2021	alny	Valuation Allowances And Reserves Sales Credit Payment Current ValuationAllowancesAndReservesSalesCreditPaymentCurrent	87928000	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5600000	USD
CY2021	alny	Valuation Allowances And Reserves Sales Credit Payment Prior ValuationAllowancesAndReservesSalesCreditPaymentPrior	63841000	USD
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	131316000	USD
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	34875000	USD
CY2020	alny	Valuation Allowances And Reserves Provision Related To Current Period Sales ValuationAllowancesAndReservesProvisionRelatedToCurrentPeriodSales	114058000	USD
CY2020	alny	Valuation Allowances And Reserves Sales Credit Payment Current ValuationAllowancesAndReservesSalesCreditPaymentCurrent	49585000	USD
CY2020	alny	Valuation Allowances And Reserves Sales Credit Payment Prior ValuationAllowancesAndReservesSalesCreditPaymentPrior	4241000	USD
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	95107000	USD
CY2021	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	56400000	USD
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	73266000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	33542000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	88627000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	120021000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	62900000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	54400000	USD
CY2021	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-17100000	USD
CY2020	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-11100000	USD
CY2019	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-1100000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	14754000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	63460000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	100942000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	16149000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7005000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12693000	USD
CY2021Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	122701000	USD
CY2020Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	92302000	USD
CY2021Q4	alny	Capitalized Inventory CapitalizedInventory	7100000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	642373000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	569376000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	140415000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	104347000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	501958000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	465029000	USD
CY2021Q4	alny	Accrued Product Rebates And Discounts AccruedProductRebatesAndDiscounts	131279000	USD
CY2020Q4	alny	Accrued Product Rebates And Discounts AccruedProductRebatesAndDiscounts	94242000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	93583000	USD
CY2020Q4	alny	Accrued Pre Clinical Clinical Trial And Manufacturing Current AccruedPreClinicalClinicalTrialAndManufacturingCurrent	46506000	USD
CY2021Q4	alny	Accrued Licensing And Collaboration Agreements AccruedLicensingAndCollaborationAgreements	22843000	USD
CY2020Q4	alny	Accrued Licensing And Collaboration Agreements AccruedLicensingAndCollaborationAgreements	15424000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	17784000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11501000	USD
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2020Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	41216000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	46151000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	49587000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	395174000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	355909000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	819975000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	819975000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	496580000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	547178000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2178000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2178000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2466000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2450000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	822153000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499046000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	549628000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-7626000	USD
CY2020	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-522000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7104000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	12297000	USD
CY2021	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	1934000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10363000	USD
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	77.50
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.14
CY2020	alny	Fair Value Assets Level2 To Level1 Transfers Number FairValueAssetsLevel2ToLevel1TransfersNumber	1	asset
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1605245000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1639000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1603615000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1352834000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	463000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	115000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1353182000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381900000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	54998000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1548617000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1333182000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1603615000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1353182000	USD
CY2021Q4	alny	Number Of Facilities Leased NumberOfFacilitiesLeased	3	facility
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	59500000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	50700000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	52400000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	45359000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	42271000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	18271000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	11049000	USD
CY2021	us-gaap	Lease Cost LeaseCost	63630000	USD
CY2020	us-gaap	Lease Cost LeaseCost	53320000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	41900000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	38000000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	41783000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	47188000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	44421000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	42936000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	40246000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	287013000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	503587000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	181692000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	321895000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40548000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	281347000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	321895000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	alny	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Shares Of Common Stock Reserved For Future Issuance Under Stock Options ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsSharesOfCommonStockReservedForFutureIssuanceUnderStockOptions	18863133	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	165717000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	139873000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	174841000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	3327000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	571000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	3403000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	139873000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	165717000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	174841000	USD
CY2017Q2	alny	Employee Stock Purchase Plan Offered Period EmployeeStockPurchasePlanOfferedPeriod	P6M
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-794729000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-682859000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-597602000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-57415000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-172741000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-287651000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-852144000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-855600000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-885253000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	293000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	61000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-394000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3154000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	5837000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3232000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3447000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5898000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2838000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	393000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	394000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2767000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3610000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2369000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2767000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3217000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1975000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	680000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2681000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	863000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3200000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2800000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	745985000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	537382000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	342431000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	301792000	USD
CY2021Q4	alny	Deferred Tax Assets Sale Of Future Royalties DeferredTaxAssetsSaleOfFutureRoyalties	302217000	USD
CY2020Q4	alny	Deferred Tax Assets Sale Of Future Royalties DeferredTaxAssetsSaleOfFutureRoyalties	259014000	USD
CY2021Q4	alny	Deferred Tax Assets Leasing Arrangement DeferredTaxAssetsLeasingArrangement	71859000	USD
CY2020Q4	alny	Deferred Tax Assets Leasing Arrangement DeferredTaxAssetsLeasingArrangement	70402000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	76612000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	84946000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	84946000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	59349000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	67530000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	302121000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	148168000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	48242000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	32725000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1948816000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1501959000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	13170000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	10812000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	16693000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	12766000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	50562000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	50323000	USD
CY2021Q4	alny	Deferred Tax Liabilities Change In Accounting Method Adjustment DeferredTaxLiabilitiesChangeInAccountingMethodAdjustment	50380000	USD
CY2020Q4	alny	Deferred Tax Liabilities Change In Accounting Method Adjustment DeferredTaxLiabilitiesChangeInAccountingMethodAdjustment	71812000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1808992000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1349729000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	9019000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	6517000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.052
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.045
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.046
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.022
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	-0.045
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	-0.033
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	-0.037
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.010
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.015
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.017
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.035
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.069
CY2021	alny	Effective Income Tax Rate Reconciliation Transfer Of Intellectual Property Percent EffectiveIncomeTaxRateReconciliationTransferOfIntellectualPropertyPercent	0.201
CY2020	alny	Effective Income Tax Rate Reconciliation Transfer Of Intellectual Property Percent EffectiveIncomeTaxRateReconciliationTransferOfIntellectualPropertyPercent	0.123
CY2019	alny	Effective Income Tax Rate Reconciliation Transfer Of Intellectual Property Percent EffectiveIncomeTaxRateReconciliationTransferOfIntellectualPropertyPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.027
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2021	alny	Effective Income Tax Rate Reconciliation Revaluation Of Deferred Credits Due To Rate Change EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredCreditsDueToRateChange	0.011
CY2020	alny	Effective Income Tax Rate Reconciliation Revaluation Of Deferred Credits Due To Rate Change EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredCreditsDueToRateChange	0
CY2019	alny	Effective Income Tax Rate Reconciliation Revaluation Of Deferred Credits Due To Rate Change EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredCreditsDueToRateChange	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.538
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.359
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.210
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	459300000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	303700000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	185900000	USD

Files In Submission

Name	View Source	Status
0001178670-22-000013-index-headers.html	Edgar Link	pending
0001178670-22-000013-index.html	Edgar Link	pending
0001178670-22-000013.txt	Edgar Link	pending
0001178670-22-000013-xbrl.zip	Edgar Link	pending
alny-20211231.htm	Edgar Link	pending
alny-20211231.xsd	Edgar Link	pending
alny-20211231_cal.xml	Edgar Link	unprocessable
alny-20211231_def.xml	Edgar Link	unprocessable
alny-20211231_g1.jpg	Edgar Link	pending
alny-20211231_g2.jpg	Edgar Link	pending
alny-20211231_g3.jpg	Edgar Link	pending
alny-20211231_htm.xml	Edgar Link	completed
alny-20211231_lab.xml	Edgar Link	unprocessable
alny-20211231_pre.xml	Edgar Link	unprocessable
alny2021q4exhibit1011.htm	Edgar Link	pending
alny2021q4exhibit1012.htm	Edgar Link	pending
alny2021q4exhibit1070.htm	Edgar Link	pending
alny2021q4exhibit211.htm	Edgar Link	pending
alny2021q4exhibit231.htm	Edgar Link	pending
alny2021q4exhibit311.htm	Edgar Link	pending
alny2021q4exhibit312.htm	Edgar Link	pending
alny2021q4exhibit321.htm	Edgar Link	pending
alny2021q4exhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2021 Form 10-K Financial Statement

#000117867022000013 Filed on February 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2021 Form 10-K Financial Statement

#000117867022000013 Filed on February 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny